OTTAWA, Nov. 15 /CNW/ - Liponex Inc. (TSX:LPX), a biopharmaceutical company specializing in developing advanced products related to High Density Lipoprotein (HDL), often called “good cholesterol,” announced that a presentation by Shawn Hopewell and colleagues from the University of Ottawa Heart Institute entitled “Phosphatidylinositol acts through mitogen and stress activated protein kinase pathways to stimulate secretion of apoA-I” was made yesterday at the American Heart Association 2006 Scientific Sessions held in Chicago, Illinois. Phosphatidylinositol (“PI”) is the active ingredient in CRD5, a novel therapeutic being developed by Liponex for the treatment of dyslipidemia and heart disease.
